Navigation Links
Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
Date:5/3/2012

MOUNTAIN VIEW, Calif., May 3, 2012 /PRNewswire/ -- Alarm bells are ringing loud and clear as diabetes has grown to epidemic proportions worldwide, triggering intensive ophthalmic research into vision-compromising comorbidities. The Centers for Disease Control and Prevention predicts that diabetic retinopathy will triple from 5.5 million in 2005 to 16.0 million in 2050. As diabetes is the leading cause of blindness in working age people, improved treatments are urgently needed. The presence of novel biopharmaceuticals as well as advancements in formulation technology has boosted the outlook for the U.S. retinal therapeutics market.

Analysis from Frost & Sullivan's (http://www.pharma.frost.com) U.S. Retinal Therapeutics Market research estimates revenues in the age-related macular degeneration (AMD) segment of the market to reach $2.26 billion by 2016. Revenues in the diabetic macular edema (DME) segment are expected to reach $455.2 million by 2016.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company Web site, city, state and country.

"While the cannibalization of Roche/Genentech profits (i.e., Avastin and Lucentis) may sound like a market challenge for that company versus a driver for the market, the very availability of these two highly effective, novel medications is expected to continue to drive this previously underserved market," said a Frost & Sullivan research analyst. "Moreover, the absence of laws and regulations permitting the manufacture of generic equivalents of biologics ensures that these therapies will remain under patent protection until 2019."

Developing therapies to treat diseases of the back of the eye is complex and, as a result, there is strong market opportunity for wet AMD drugs. The scope for wet AMD drugs such as Lucentis and Avastin is being further expanded by penetration into other back-of-the-eye conditions such as DME and retinal vein occlusion.

Another factor uplifting market prospects is the aging baby boomer population in the United States, which will create a demand upsurge for ophthalmics that improve, restore and preserve sight. Ease of use of therapy is also expected to be of considerable importance among this growing elderly patient base. This has opened up new avenues of opportunity for pharmaceutical and drug delivery companies, enabling a boost in their revenues.

Established treatment alternatives impede the success of new DME therapies. Although Lucentis may achieve its primary endpoint in its trials for DME, it is unlikely to achieve the same level of commercial success it did with wet AMD due to the cost and relative effectiveness of existing treatment options. Lucentis must demonstrate significant clinical efficacy to justify the costly monthly injections required to sustain visual acuity gains in the DME patient population.

Long, drawn out and costly clinical trials will deter new market entrants. In addition, difficulties in finding patients willing to participate in clinical trials and the lack of funds for costly and lengthy trials limit drug companies' abilities to introduce new products into the market. Several pharmaceutical and drug delivery companies are ramping up research efforts to improve the delivery of drugs to the back of the eye.

"Trends indicate that Avastin will remain the most-utilized pharmacologic therapy for the treatment of retinal vascular disease," said the research analyst. "By 2016, Regeneron is expected to supplant Roche/Genentech as the largest revenue contributor to the market."

U.S. Retinal Therapeutics Market is part of the Life Sciences Growth Partnership Service program, which also includes research in the following markets: Analysis of the United States Glaucoma Pharmaceuticals Market, Specialty Physicians Discuss their Opinions of the United States Biosimilars Market, Analysis of the United States Contract Manufacturing Outsourcing Market, Strategic Analysis of the U.S. Research Antibodies Market, and Analysis of the U.S. Clinical Laboratory Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

U.S. Retinal Therapeutics Market

N85D

Contact:
Britni Myers
Corporate Communications – North America
P: 210.477.8481
F: 210.348.1003
E: britni.myers@frost.com

http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
3. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
4. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
5. Widening Application Range to Boost MRI Markets in Eastern Europe, Says Frost & Sullivan
6. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
7. Frost & Sullivan Recognizes Holst Centre and imec for Its Path Breaking Wearable Energy Harvester Technology
8. Frost & Sullivan Recognizes Japan Stent Technology for Its Pioneering Coronary Stent Design
9. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
10. Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough
11. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... SAN DIEGO , Oct. 12, 2017 ... has recognized the company with their  2017 New Product Innovation ... is based on extensive primary and secondary medical device market ... AVACEN Medical, through its first-to-market OTC, drug-free pain relief product, ... a unique approach to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
Breaking Medicine News(10 mins):